AXGN — AxoGen, Inc.

Summary of Axogen (AXGN) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $59.9 million, up 21.3% year-over-year.
• Full Year Revenue: $225.2 million, reflecting a 20.2% increase from 2024.
• Adjusted EBITDA: Q4 adjusted EBITDA was $6.5 million; full year adjusted EBITDA was $27.9 million, up 41% from 2024.
• Gross Margin: Q4 gross margin at 74.1%, down from 76.1% year-over-year; full year gross margin at 74.3%.
• Net Loss: Q4 net loss of $13.2 million ($0.28 per share), compared to a net income of $500,000 in Q4 2024; full year net loss of $15.7 million ($0.34 per share).
• Cash Position: Increased by $6 million to $45.5 million, demonstrating positive cash flow for the year.

2. Strategic Updates and Business Highlights

• Market Growth: Achieved double-digit growth across all three target markets: extremities, oral maxillofacial, and breast.
• FDA Approval: Received FDA approval for Avance Nerve Graft, establishing it as the first FDA-approved biologic for peripheral nerve repair, enhancing market position.
• Sales Force Expansion: Increased sales representatives across all markets, with plans to continue growing the team in 2026.
• High-Potential Accounts: 61% of revenue growth came from high-potential accounts, with a goal to maintain this percentage in 2026.
• Education Initiatives: Exceeded training targets for surgeons, with plans to expand educational programs in 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected growth of at least 18%, targeting total revenue of at least $265.7 million.
• Gross Margin Expectations: Anticipated to remain in the range of 74% to 76% for 2026, with improvements expected in 2027.
• Free Cash Flow: Expected to be positive for the full year 2026, despite higher cash burn anticipated in Q1.

4. Bad News, Challenges, or Points of Concern

• Net Losses: Continued net losses in Q4 and for the full year raise concerns about profitability.
• Operating Expenses: Significant increase in operating expenses, particularly in sales and marketing, which rose nearly 5 percentage points as a percentage of revenue in Q4.
• Gross Margin Pressure: Margins are under pressure due to increased product costs associated with transitioning Avance to a biologic, with potential impacts on profitability.
• Market Adoption: While there is momentum, the company must manage expectations regarding the pace of adoption and market penetration, particularly in the prostate segment, which is not expected to contribute significantly to revenue in 2026.

5. Notable Q&A Insights

• Conservative Guidance: Management characterized the 18% revenue growth guidance as prudent, emphasizing the need for careful management of customer creation processes.
• Reimbursement Dynamics: Discussions on the impact of CMS reimbursement changes highlighted that while payments have increased, the transition to outpatient settings will take time and is not expected to significantly impact the breast segment.
• Clinical Evidence: Plans for clinical studies in breast and prostate markets were discussed, with a focus on establishing adequate clinical evidence to support product adoption.
• Sales Force Strategy: Management indicated that the current sales force size is still far from achieving full market coverage, particularly in the extremities and breast markets, suggesting ongoing expansion efforts.

This summary encapsulates the key points from Axogen's Q4 2025 earnings call, providing a clear overview of the company's financial performance, strategic initiatives, future outlook, and challenges.